Robert Lustig, MD discusses his previous presentation at Emery Pharma with the CEO of Emery Pharma, Ron Najafi, Ph.D. In summary, Dr. Lustig discusses the rise of type 2 diabetes in children and challenges the notion that it is a chronic, unrelenting, and genetic disease. He argues that the increase in type 2 diabetes is due to exposure to certain factors, primarily ultra-processed foods containing high amounts of sugar, trans fats, and other substances that affect Liver, the microbiome and promote inflammation. Dr. Lustig also emphasizes the importance of distinguishing between metabolically healthy and unhealthy obesity and suggests biomarkers such as waist circumference, fasting insulin levels, uric acid levels, and ALT levels to assess metabolic health. Regarding statins, Dr. Lustig acknowledges their effectiveness for secondary prevention in individuals who have already experienced a heart attack but questions their use for primary prevention. He mentions that statins can have mitochondrial toxicity and may increase the risk of diabetes. Lastly, Dr. Lustig suggests enjoying desserts in moderation and as an occasional treat, while advocating for the reduction of sugar in processed foods.
about Emery Pharma: